Evolus, Inc. EOLS
6.74 USD -0.06 (-0.88%)
Nov 6, 2026, 11:59 AM EST
6.64 Day range 6.83
3.86 52-week range 9.31
- YTD
- +1.28%
- 1 year
- -6.20%
- Market cap
- 446.11M
- Revenue (ttm)
- 248.33M
- Profit margin
- -22.33%
- EPS (ttm)
- -0.48
- Shares out
- 63.32M
- Forward P/E
- 54.20
- YTD return
- +1.28%
- 1-year return
- -6.20%
- Volume
- 247.29K
- Avg volume
- 878.52K
- Open
- 6.74
- Previous close
- 6.80
- Day's range
- 6.64 – 6.83
- 52-week range
- 3.86 – 9.31
- Beta
- 1.31
- Analysts
- Buy
- Price target
- 23.43 (+247.9%)
- Earnings date
- Jul 31, 2024
5D -0.99 (-12.71%)
Key statistics
- Enterprise value
- 734.41M
- PEG ratio
- 0.00
- Price / sales
- 2.76
- Price / book
- 116.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 22.10%
- Free cash flow
- -7.40M
- Total cash
- 85.03M
- Total debt
- 129.88M
- Return on equity
- 0.00%
- Short % of float
- 8.41%
- 50-day average
- 14.00
- 200-day average
- 13.56
Analyst view
Consensus: buy
Buy
Price target (mean) 23.43 +247.9% upside
Now 6.74
- Target (low)
- 20.00
- Target (mean)
- 23.43
- Target (high)
- 27.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy4
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Jul 31, 2024
Expected Jul 31, 2024. Consensus EPS estimate -0.001.
Financials — quick view
EOLS Revenue — quarterly 84.08M
EOLS Net income — quarterly -8.05M
EOLS EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.08 | -0.19 | -0.11 | -137.50% |
| Jul 31, 2024 | Jun 1, 2024 | -0.04 | -0.07 | -0.03 | -75.00% |
| Jul 31, 2024 | Jun 1, 2024 | -0.04 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.07 | -0.13 | -0.06 | -85.71% |
| May 7, 2024 | Mar 1, 2024 | -0.07 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Sep 13, 2024 | Barclays | main | Overweight | Overweight |
| Sep 13, 2024 | Needham | reit | Buy | Buy |
About Evolus, Inc.
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- evolus.com
News
Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript 
What Evolus (EOLS) Said on Its Q3 Earnings Call 
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates 
Evolus Q3 2026 Earnings Call Transcript 
Evolus Affirms FY2026 Sales Guidance of $330.000M-$337.000M vs $334.100M Est 
Evolus Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $78.000M Beat $77.662M Estimate 
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS 
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug 
Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role
Your note
Sign in to keep a note on EOLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVELAR RUI L. | Officer | Sale | May 9, 2024 | 368,847 |
| BEAVER SANDRA | Chief Financial Officer | Sale | Sep 5, 2024 | 148,502 |
| BLANK SIMONE | Director | Stock Award(Grant) | Feb 6, 2024 | 552,530 |
| GILL DAVID N. | Director | Sale | May 13, 2024 | 33,964 |
| HAYMAN ROBERT | Director | Stock Award(Grant) | Feb 6, 2024 | 65,222 |
| MALIK VIKRAM | Director | Sale | Jun 2, 2024 | 246,514 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 8.46% | 5,356,622 | 58.07M | Sep 29, 2024 |
| Tang Capital Management, LLC | 7.66% | 4,847,399 | 52.55M | Sep 29, 2024 |
| Blackrock Inc. | 6.68% | 4,230,149 | 45.85M | Sep 29, 2024 |
| Vanguard Group Inc | 5.05% | 3,195,331 | 34.64M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 4.46% | 2,824,849 | 30.62M | Sep 29, 2024 |
| Caligan Partners, LP | 3.46% | 2,193,488 | 23.78M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.66% | 1,684,167 | 18.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.25% | 1,422,214 | 15.42M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.12% | 708,633 | 7.68M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.89% | 564,794 | 6.12M | Aug 30, 2024 |
| Oberweis Micro-Cap Portfolio | 0.81% | 514,900 | 5.58M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.78% | 492,517 | 5.34M | Oct 30, 2024 |